Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)

Study Summary

This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).

Interventions

Study Locations

Facility	City	State	Country
Zhejiang Provincal People's Hospital	Hangzhou	Zhejiang	China

Official Trial Information

View on ClinicalTrials.gov